Ruediger Klapdor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2450617/publications.pdf

Version: 2024-02-01

40 659 16
papers citations h-index

h-index g-index

43 1173
times ranked citing authors

610901

24

43 all docs 43 docs citations

#	Article	IF	CITATIONS
1	Association of preoperative cone biopsy with recurrences after radical hysterectomy. Archives of Gynecology and Obstetrics, 2022, 305, 215-222.	1.7	9
2	The Fusion of MRI and CT in the Planning of Brachytherapy for Cancer of the Uterine Cervix. Applied Sciences (Switzerland), 2022, 12, 634.	2.5	1
3	Risk for Pelvic Metastasis and Role of Pelvic Lymphadenectomy in Node-Positive Vulvar Cancer-Results from the AGO-VOP.2 QS Vulva Study. Cancers, 2022, 14, 418.	3.7	О
4	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer Journal of Clinical Oncology, 2022, 40, 5599-5599.	1.6	0
5	SOCIUS Mentoring—A Novel Course to Encourage Students for a Career as Surgical Oncologists. Medical Sciences (Basel, Switzerland), 2022, 10, 35.	2.9	1
6	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
7	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.7	6
8	p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft GynÃkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group. American Journal of Obstetrics and Gynecology, 2021, 224, 595.e1-595.e11.	1.3	21
9	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		О
10	NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44. Biomedicines, 2021, 9, 1339.	3.2	18
11	Sentinel lymph node biopsy in vulvar cancer: status, level of knowledge, and counseling in outpatient setting. Archives of Gynecology and Obstetrics, 2020, 302, 1001-1007.	1.7	О
12	Radical hysterectomy for early cervical cancer: what shall we do after the LACC trial?. Archives of Gynecology and Obstetrics, 2020, 302, 289-292.	1.7	7
13	Quality of Life after Bilateral and Contralateral Prophylactic Mastectomy with Implant Reconstruction. Breast Care, 2020, 15, 519-526.	1.4	8
14	Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 study. International Journal of Gynecological Cancer, 2020, 30, 920-926.	2.5	3
15	Peritoneal contamination with <scp>ICG</scp> â€stained cervical secretion as surrogate for potential cervical cancer tumor cell dissemination: A proofâ€ofâ€principle study for laparoscopic hysterectomy. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 1398-1403.	2.8	27
16	Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study. Gynecologic Oncology, 2019, 154, 565-570.	1.4	16
17	Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 660.	4.1	70
18	Should we really abandon inguinal lymphadenectomy in the treatment of vulvar cancer?. Acta Obstetricia Et Gynecologica Scandinavica, 2019, 98, 399-399.	2.8	1

#	Article	IF	CITATIONS
19	p53 and p16 expression profiles reveal three prognostically relevant subgroups in vulvar cancer: A TMA based study by the AGO-CaRE-translational study group Journal of Clinical Oncology, 2019, 37, 5592-5592.	1.6	8
20	The influence of obesity on tumor recurrence in vulvar cancer patients Journal of Clinical Oncology, 2019, 37, e17130-e17130.	1.6	2
21	Sentinel lymphadenectomy in cervical cancer using near infrared fluorescence from indocyanine green combined with technetiumâ€99mâ€nanocolloid. Lasers in Surgery and Medicine, 2018, 50, 994-1001.	2.1	16
22	Postoperative anatomic and qualityâ€ofâ€ife outcomes after vaginal sacrocolporectopexy for vaginal vault prolapse. International Journal of Gynecology and Obstetrics, 2017, 137, 86-91.	2.3	2
23	Application of sentinel lymph node dissection in gynecological cancers: results of a survey among German hospitals. Archives of Gynecology and Obstetrics, 2017, 295, 713-720.	1.7	10
24	Photodynamic diagnosis with 5â€aminolevulinic acid for intraoperative detection of peritoneal metastases of ovarian cancer: A feasibility and dose finding study. Lasers in Surgery and Medicine, 2017, 49, 169-176.	2.1	23
25	Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 Study. Annals of Surgical Oncology, 2017, 24, 1314-1321.	1.5	30
26	Sentinel Lymphadenectomy in Vulvar Cancer Using Near-Infrared Fluorescence From Indocyanine Green Compared With Technetium 99m Nanocolloid. International Journal of Gynecological Cancer, 2017, 27, 805-812.	2.5	31
27	Association between intraabdominal pressure during gynaecologic laparoscopy and postoperative pain. Archives of Gynecology and Obstetrics, 2017, 295, 1191-1199.	1.7	9
28	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	1.8	28
29	Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor–Based Immunotherapy and Chemotherapy. Human Gene Therapy, 2017, 28, 886-896.	2.7	65
30	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	6.4	16
31	The Value of Partial HPV Genotyping After Conization of Cervical Dysplasias. Geburtshilfe Und Frauenheilkunde, 2017, 77, 887-893.	1.8	10
32	Groin Recurrences in Node Negative Vulvar Cancer Patients After Sole Sentinel Lymph Node Dissection. International Journal of Gynecological Cancer, 2017, 27, 166-170.	2.5	33
33	Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1114-1124.	2.5	32
34	Rare ATAD5 missense variants in breast and ovarian cancer patients. Cancer Letters, 2016, 376, 173-177.	7.2	21
35	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	6.4	39
36	Late radiation side effects, cosmetic outcomes and pain in breast cancer patients after breast-conserving surgery and three-dimensional conformal radiotherapy. Strahlentherapie Und Onkologie, 2016, 192, 8-16.	2.0	33

#	Article	IF	CITATIONS
37	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
38	Radiofrequency endometrial ablation for the treatment of heavy menstrual bleeding among women at high surgical risk. International Journal of Gynecology and Obstetrics, 2015, 131, 123-128.	2.3	7
39	Value and Advantages of Preoperative Sentinel Lymph Node Imaging With SPECT/CT in Cervical Cancer. International Journal of Gynecological Cancer, 2014, 24, 295-302.	2.5	31
40	Evaluation of active camera control systems in gynecological surgery: construction, handling, comfort, surgeries and results. Archives of Gynecology and Obstetrics, 2014, 289, 341-348.	1.7	7